Simcere Pharmaceutical Group
http://en.simcere.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Simcere Pharmaceutical Group
Pharma Not Immune From Coming Antitrust Wave In China
China's historic antitrust fine against Alibaba indicates regulatory attention to anticompetitive practices is mounting. While the pharma sector remains segmented, investigators appear to be taking a generally more sophisticated approach to transgressions.
Alibaba's Historic $2.8bn Fine Signals Coming Antitrust Wave In China
China's historic antitrust fine against Alibaba indicates regulatory attention to anticompetitive practices is mounting. Past cases show the pharma sector is not immune and while it remains segmented, investigators appear to be taking a generally more sophisticated approach to transgressions.
Asia Deal Watch: Vibegron’s Vagabond Journey Continues With Eisai Acquiring Partial Asian Rights
Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio
As China Prices Drop, Junshi Looks To Coherus To Take PD-1 Global
After Novartis, US firm Coherus leaps into the China immuno-oncology fray by licensing rights to innovative drugs from Shanghai's Junshi.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Jilin Boda Pharmaceutical Co., Ltd.
- ChinaVax
- Master Luck Corporation Limited
- Jiangsu Simcere Pharmaceutical R&D Co., Ltd.
- Jiangsu Yanshen Biological Technology Stock Co., Ltd.
- Nanjing Tung Chit Pharmaceutical Co., Ltd.
- Shandong Simcere Medgenn Bio-Pharmaceutical Co. Ltd.
- Wuhu Zhong Ren Pharmaceutical Co. Ltd.
- Xiangao Investment Company Ltd.
- Yantai Medgenn Co. Ltd.
- Jiangsu Simcere Pharmaceutical Co., Ltd.